Elanco Animal Health Inc (NYSE: ELAN) shares surged 5.24% in pre-market trading on Wednesday following the company's announcement of better-than-expected first-quarter results and an increase in its full-year revenue guidance.

The animal health company reported first-quarter adjusted earnings of $0.37 per share, significantly beating the analyst consensus estimate of $0.31. This represents a 19.35% surprise to the upside and an 8.82% increase from the same period last year. Quarterly revenue came in at $1.19 billion, surpassing the analyst estimate of $1.17 billion by 2.11%. The strong performance was driven by organic growth and operational efficiencies.

In light of the robust results, Elanco raised its 2025 revenue guidance to a range of $4.51 billion to $4.58 billion, up from the previous forecast of $4.45 billion to $4.51 billion. The company also increased its 2025 innovation revenue target to $660 million to $740 million, signaling confidence in its product pipeline. Despite headwinds from tariffs and foreign exchange rates, Elanco maintained its full-year adjusted earnings guidance of $0.80 to $0.86 per share, demonstrating the company's ability to navigate challenges while delivering growth.